Phathom Pharmaceuticals (PHAT) holders disclose 2.7% passive stake
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Phathom Pharmaceuticals, Inc. received an amended Schedule 13G/A showing that several Millennium-affiliated entities report passive, sub-5% positions in its common stock as of 12/31/2025. Integrated Core Strategies (US) LLC reports beneficial ownership of 1,255,161 shares, representing 1.6% of the class, with shared voting and dispositive power over those shares. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 2,082,180 shares, or 2.7% of the class, all with shared voting and dispositive power. The filers state that the securities are not held for the purpose of changing or influencing control of Phathom Pharmaceuticals.
Positive
- None.
Negative
- None.
FAQ
What ownership stake in Phathom Pharmaceuticals (PHAT) does Millennium report?
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 2,082,180 Phathom Pharmaceuticals common shares, representing 2.7% of the class as of 12/31/2025.
Is the Millennium stake in Phathom Pharmaceuticals reported as passive?
Yes. The filers certify that the Phathom Pharmaceuticals securities were not acquired and are not held for the purpose or effect of changing or influencing control of the issuer.
Who are the reporting persons on this Phathom Pharmaceuticals Schedule 13G/A?
The reporting persons are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander.
What type of securities do the reporting persons hold in Phathom Pharmaceuticals (PHAT)?
The reporting persons disclose holdings of common stock of Phathom Pharmaceuticals, Inc., with a par value of $0.0001 per share, identified by CUSIP 71722W107.
What does Item 5 indicate about Millennium’s ownership level in Phathom Pharmaceuticals?
Item 5 states that the reporting persons each hold 5 percent or less of Phathom Pharmaceuticals’ common stock class.